Study of a drug for stroke patients after blood clot treatment
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke affecting the front part of the brain within the last 24 hours.
- Your stroke symptoms are moderate to moderately severe (NIHSS score 4 to 25).
- You already received clot-busting medicine or a procedure to remove the clot.
- You were able to do daily activities on your own before the stroke.
- You do not have a history of bleeding problems, liver or kidney disease, or recent use of certain blood thinners or blood pressure medicines.
- You are not allergic to the study drug or related medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
This trial tests a drug called Human Urinary Kallidinogenase to see if it can help people recover better after a recent stroke caused by a blockage in the front part of the brain. It is for patients who have mild to moderate symptoms and can start treatment within 2 days of the stroke.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
This trial tests a drug called urinary kallidinogenase to see if it helps people who have had a stroke caused by a large artery in the brain becoming narrowed or blocked. It is for those who can be treated within 48 hours of symptoms starting.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.